Predictive miRNAs Patterns in Blood of Breast Cancer Patients Demonstrating Resistance Towards Neoadjuvant Chemotherapy

被引:1
作者
Fan, Jingjing [1 ]
Tang, Yunjian [1 ]
Wang, Kunming [1 ]
Yang, Shu [1 ]
Ma, Binlin [1 ,2 ]
机构
[1] Xinjiang Med Univ, Dept Breast & Thyroid Surg, Canc Hosp, Urumqi 830011, Xinjiang, Peoples R China
[2] Xinjiang Med Univ, Canc Hosp, 789 Suzhou East St, Urumqi, Xinjiang, Peoples R China
来源
BREAST CANCER-TARGETS AND THERAPY | 2023年 / 15卷
关键词
breast cancer; neoadjuvant chemotherapy; drug resistance; serum microRNAs; nomogram model; 5-miRNAs; GO and KEGG enrichment analyses; CHEMORESISTANCE; DIAGNOSIS; MICRORNAS;
D O I
10.2147/BCTT.S415080
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The effect of chemotherapy in patients with breast cancer (BC) is uncertain. This study attempted to analyze serum microRNAs (miRNAs) in NAC resistant and sensitive BC patients and develop a miRNA-based nomogram model. To further help clinicians make treatment decisions for hormone receptor-positive patients.Methods: A total of 110 BC patients with NAC were recruited and assigned in sensitive and resistant group, and 4 sensitive patients and 3 resistant patients were subjected to high-throughput sequencing. The functions of their target genes were analyzed by GO and KEGG. Five BC-related reported miRNAs were selected for expression pattern measurement by RT-qPCR and multivariate logistic analysis. The nomogram model was developed using R 4.0.1, and its predictive efficacy, consistency and clinical application value in development and validation groups were evaluated using ROC, calibration and decision curves.Results: There were 44 differentially-expressed miRNAs in resistant BC patients. miR-3646, miR-4741, miR-6730-3p, miR-6831-5p and miR-8485 were candidate for resistance diagnosis in BC. Logistic multiple regression analysis showed that miR-4741 (or = 0.30, 95% CI = 0.08-0.63, P = 0.02) and miR-6831-5p (or = 0.48, 95% CI = 0.24-0.78, P = 0.01) were protective factors of BC resistance. The ROC curves showed a sensitivity of 0.884 and 0.750 for miR-4741 and miR-6831-5P as markers of resistance, suggesting that they can be used as independent risk factors for BC resistance. The other 3 miRNAs can be used as calibration factors to establish the risk prediction model of resistance in BC. In risk model, the prediction accuracy of resistance of BC is about 78%. 5-miRNA signature diagnostic models can help clinicians provide personalized treatment for NAC resistance BC patients to improve patient survival.Conclusion: MiR-4741 and miR-6831-5p are independent risk factors for breast cancer resistance. This study constructed a nomogram model of NAC resistance in BC based on 5 differentially-expressed serum miRNAs.
引用
收藏
页码:591 / 604
页数:14
相关论文
共 50 条
  • [31] Mammographic breast density: Predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients
    Elsamany, S.
    Alzahrani, A.
    Abozeed, W. N.
    Rasmy, A.
    Farooq, M. U.
    Elbiomy, M. A.
    Rawah, E.
    Alsaleh, K.
    Abdel-Aziz, N. M.
    BREAST, 2015, 24 (05) : 576 - 581
  • [32] Predictive and prognostic effect of HO-1 expression in breast cancer patients undergoing neoadjuvant chemotherapy
    Qixing Tan
    Qinghong Qin
    Zhen Huang
    Bin Lian
    Qinguo Mo
    Changyuan Wei
    Breast Cancer Research and Treatment, 2022, 193 : 393 - 403
  • [33] Dynamic ultrasound-based modeling predictive of response to neoadjuvant chemotherapy in patients with early breast cancer
    Wang, Xinyi
    Zhang, Yuting
    Yang, Mengting
    Wu, Nan
    Wang, Shan
    Chen, Hong
    Zhou, Tianyang
    Zhang, Ying
    Wang, Xiaolan
    Jin, Zining
    Zheng, Ang
    Yao, Fan
    Zhang, Dianlong
    Jin, Feng
    Qin, Pan
    Wang, Jia
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [34] Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy
    Wu, Ziping
    Zhang, Lei
    Xu, Shuguang
    Lin, Yanping
    Yin, Wenjin
    Lu, Jinglu
    Sha, Rui
    Sheng, Xiaonan
    Zhou, Liheng
    Lu, Jinsong
    CANCER CELL INTERNATIONAL, 2019, 19 (1)
  • [35] Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics
    Yamada, Miki
    Jinno, Hiromitsu
    Naruse, Saki
    Isono, Yuka
    Maeda, Yuka
    Sato, Ayana
    Matsumoto, Akiko
    Ikeda, Tatsuhiko
    Sugimoto, Masahiro
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 207 (02) : 393 - 404
  • [36] Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer
    Todorova, Valentina K.
    Byrum, Stephanie D.
    Gies, Allen J.
    Haynie, Cade
    Smith, Hunter
    Reyna, Nathan S.
    Makhoul, Issam
    CURRENT ONCOLOGY, 2022, 29 (02) : 613 - 630
  • [37] Predictive biomarkers of survival after neoadjuvant chemotherapy for breast cancer
    Galvez-Nino, Marco
    Roque, Katia
    Angel Bernabe, Luis
    Castillo, Miluska
    Sanchez, Joselyn
    Landa Baella, Maria
    Calderon, Gabriela
    De la Cruz, Miguel
    Dunstan, Jorge
    Abugatas, Julio
    Cotrina, Jose
    Castaneda, Carlos
    Gomez, Henry
    CANCER RESEARCH, 2020, 80 (04)
  • [38] Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
    Isca, Chrystel
    Piacentini, Federico
    Mastrolia, Ilenia
    Masciale, Valentina
    Caggia, Federica
    Toss, Angela
    Piombino, Claudia
    Moscetti, Luca
    Barbolini, Monica
    Maur, Michela
    Dominici, Massimo
    Omarini, Claudia
    CANCERS, 2021, 13 (19)
  • [39] Neoadjuvant chemotherapy in patients with stages II and III breast cancer
    Yuan Zhu
    Qu Xiang
    Zhang Zhong-tao
    Wang Yu
    CHINESE MEDICAL JOURNAL, 2009, 122 (24) : 2993 - 2997
  • [40] Tolerance and Outcomes of Neoadjuvant Chemotherapy in Geriatric Breast Cancer Patients
    Brown, Lauren
    Carr, Michael J.
    Sam, Christine
    Sun, Weihong
    Whiting, Junmin
    Kim, Youngchul
    Lee, M. Catherine
    JOURNAL OF SURGICAL RESEARCH, 2023, 283 : 329 - 335